Clinique Belharra

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer2 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Active, not recruiting6 trials
• Withdrawn1 trial

Lead sponsor

• Pfizer3 trials
• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 trial
• Federation Francophone de Cancerologie Digestive1 trial
• Fondation Franc.Cancerologie Digestive1 trial
• UNICANCER1 trial

Running trials

• Active, not recruiting

  Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and immunotherapy ( Pembrolizumab)

  NCT04262687· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Active, not recruiting

  Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

  NCT05617963· Phase 2· UNICANCER· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Pfizer· Source

• Active, not recruiting

  Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197· Phase 3· Pfizer· Source

• Recruiting

  Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

  NCT02885753· Phase 3· Federation Francophone de Cancerologie Digestive· Source

Closed trials

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source